Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
Cancer Biology & Therapy
|
November 1, 2005
Expression of osteopontin and HGF/met in adult soft tissue tumors
Vivien H C Bramwell, Alan B Tuck, Sylvia M Wilson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 13, 2013
Expression of both estrogen receptor-beta 1 (ER-β1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-α)-negative early breast cancer (EBC)
Y Yan, X Li, A Blanchard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 22, 2005
Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study
M A Nooij, J Whelan, V H C Bramwell, et al.
Breast Cancer Research : BCR
|
August 27, 2013
Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort
Judith-Anne W Chapman, Torsten O Nielsen, Matthew J Ellis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 11, 2011
Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials
Hans Gelderblom, Rachel C Jinks, Matthew Sydes, et al.
The Lancet. Oncology
|
September 8, 2012
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial
Penella J Woll, Peter Reichardt, Axel Le Cesne, et al.
Breast Cancer Research : BCR
|
January 24, 2014
Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial
Vivien H C Bramwell, Alan B Tuck, Judith-Anne W Chapman, et al.
Breast Cancer Research and Treatment
|
October 12, 2013
Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials
J F Hilton, N Bouganim, B Dong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 6, 2017
Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials
R Yerushalmi, B Dong, J W Chapman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2008
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
Charles D Blanke, Cathryn Rankin, George D Demetri, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
Cancer Biology & Therapy
|
November 1, 2005
Expression of osteopontin and HGF/met in adult soft tissue tumors
Vivien H C Bramwell, Alan B Tuck, Sylvia M Wilson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 13, 2013
Expression of both estrogen receptor-beta 1 (ER-β1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-α)-negative early breast cancer (EBC)
Y Yan, X Li, A Blanchard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 22, 2005
Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study
M A Nooij, J Whelan, V H C Bramwell, et al.
Breast Cancer Research : BCR
|
August 27, 2013
Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort
Judith-Anne W Chapman, Torsten O Nielsen, Matthew J Ellis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 11, 2011
Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials
Hans Gelderblom, Rachel C Jinks, Matthew Sydes, et al.
The Lancet. Oncology
|
September 8, 2012
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial
Penella J Woll, Peter Reichardt, Axel Le Cesne, et al.
Breast Cancer Research : BCR
|
January 24, 2014
Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial
Vivien H C Bramwell, Alan B Tuck, Judith-Anne W Chapman, et al.
Breast Cancer Research and Treatment
|
October 12, 2013
Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials
J F Hilton, N Bouganim, B Dong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 6, 2017
Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials
R Yerushalmi, B Dong, J W Chapman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2008
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
Charles D Blanke, Cathryn Rankin, George D Demetri, et al.
Page
of 5